Day: 2026年3月2日

TOKYO, Mar 2, 2026 - (JCN Newswire via SeaPRwire.com) - NTT DOCOMO, INC. and NEC Corporation today announced the launch of Japan’s first commercial 5G core network (5GC) on Amazon Web Services (AWS) on February 26.(1) Advanced architecture, constructed using Agentic AI,(2) enables the network to flexibly and rapidly expand capacity, such as dynamically expanding its capacity in response to sudden traffic surges, for dramatically improved reliability, flexibility and sustainability.In a separate world-first achievement(3), DOCOMO and NTT DOCOMO BUSINESS, Inc. in collaboration with NTT DOCOMO SOLUTIONS, Inc. have also successfully automated 5GC design and construction on AWS. To do this, they leveraged Agentic AI—a combination of AI and GitOps(4) in a hybrid cloud environment. This innovative approach prevents human error and reduces construction time by approximately 80% compared to conventional methods.First in Japan to Construct and Commercially Launch 5GC on AWSIn March 2022, DOCOMO and NEC started verifying 5GC network equipment operating on a hybrid cloud using AWS, aiming to enhance network deployment flexibility and reliability. The process included testing the coordinated operation of the 5GC on AWS and DOCOMO’s proprietary virtualization platform,(5) as well as ensuring carrier-grade availability and operability.(6) Connecting the two platforms presented significant challenges, including network and security design considerations, but DOCOMO and NEC successfully overcame these issues to confirm that the 5GC operates seamlessly in a hybrid cloud environment.Building on this success, DOCOMO and NEC have now implemented the necessary fault tolerance and redundancy for a commercial environment, creating a hybrid cloud that combines their virtualization platform with a public cloud. In developing this environment, DOCOMO defined the requirements, established design policies, and reviewed the implementation method for the hybrid cloud. NEC redesigned the entire architecture to establish a construction and operation model based on infrastructure as code (IaC)(7) and continuous integration/continuous delivery (CI/CD)(8) for AWS. This process incorporated AWS managed services, such as AWS CloudFormation,(9) AWS CodeBuild,(10) and AWS CodePipeline,(11) into the design.This hybrid cloud environment is expected to improve network operational efficiency and enable the flexibility and reliability required in the 5G era. For example, building the 5GC on AWS in addition to a separate virtualization platform enables flexible operations, such as rapidly expanding capacity when network demand increases due to a sudden event, and scaling down when increased capacity is no longer needed.Additionally, operational tests confirmed a power consumption reduction of approximately 70%(12) by running the 5GC on AWS Graviton2(13) processors and conducting operational tests in a hybrid cloud environment that connected the 5GC on Graviton2 with the 5GC on DOCOMO’s virtualization platform. In a commercial environment, the 5GC built on AWS Graviton3 is expected to reduce environmental impact similarly.World’s First Automation of 5GC Network from Design to Construction Using GitOps and AIDOCOMO and DOCOMO BUSINESS, in collaboration with DOCOMO SOLUTIONS, achieved the world’s first automation of 5GC design and construction using GitOps(14) and AI, aiming to prevent human error and shorten the construction period.DOCOMO and DOCOMO SOLUTIONS used GitOps to automate construction from the cloud infrastructure up to the 5GC. DOCOMO BUSINESS automated the 5GC design and construction processes, as well as the development of Agentic AI, while NTT DOCOMO SOLUTIONS implemented and verified the AWS infrastructure portion of GitOps.To minimize manual tasks, such as designing configuration values, they adopted Agentic AI with Amazon Bedrock AgentCore,(15) AWS’s agentic AI platform for building, deploying, and operating effective agents securely at scale, and the Model Context Protocol (MCP),(16) creating a new architecture integrated with GitOps.Conventionally, 5GC construction required the creation and modification of numerous complex configuration files, a process that demanded significant manpower and time. However, by implementing Agentic AI with multiple AI agents using Amazon Bedrock AgentCore, DOCOMO BUSINESS was able to automate tasks such as designing configuration values, creating settings files, and issuing construction instructions to GitOps. Consequently, they succeeded in automating everything from design to construction. As a result, the 5GC construction period was reduced by approximately 80% compared to conventional methods.In the future, the companies plan to improve access to their knowledge base and optimize task allocation among AI agents, aiming to achieve faster network speeds and higher precision. They will also expand the scope of AI utilization and accelerate efforts toward the complete automation of 5GC operations by enhancing reproducibility, reliability and operational efficiency through AI-driven generation and execution.This automated 5GC construction solution using Agentic AI is currently on display at the NTT booth (Hall 3, Stand 3M29) at the 2026 Mobile World Congress in Barcelona. Through this exhibition, DOCOMO and NEC aim to communicate the innovation and uniqueness of their world-leading communication infrastructure for an AI-powered world.Executive CommentsNobuko Hiraguchi, Executive Officer, General Manager of Core Network Design Department, NTT DOCOMO, INC.“This initiative is a major step forward in DOCOMO’s ongoing effort to advance networks. We have integrated AWS’s scalable cloud platform, which flexibly supports advanced initiatives, including AI, with NEC’s highly reliable 5GC and DOCOMO BUSINESS’s Agentic AI expertise. Also, combining on-premises and cloud technologies enhances network reliability and the ability to respond to demand. Furthermore, shortening the 5GC construction period on the public cloud through AI automation will allow us to deliver services to customers more quickly. I believe our proactive approach to embracing AI has led to this world-first achievement. DOCOMO will continue to take on new challenges to provide communication services that our customers will choose.”Takashi Sato, Corporate Senior Vice President and Managing Director, Network Solutions Business Division of NEC Corporation“NEC is proud to contribute to the transformation of communication infrastructure alongside DOCOMO and AWS by providing our 5GC software. Since 2022, we have been addressing the challenge of creating a carrier-grade 5GC network in the cloud through technical verification. This commercial deployment is the result of combining Japanese telecommunications technology with a global cloud platform to create world-leading communication infrastructure. NEC will continue to contribute to the network evolution of our telecommunications carrier partners in the future.”Yuichi Ikejiri, Deputy Senior Vice President, Innovation Center, NTT DOCOMO BUSINESS, Inc.“I am honored to have participated in this project. Agentic AI’s automated construction of 5GC will transform the core network construction process, which has traditionally required significant time and specialized knowledge for design, verification and configuration. Starting with this initiative, we will continue to leverage the power of AI to shorten service provision lead times, standardize design and construction processes, and ensure consistent quality, thereby enabling us to deliver services to the market more quickly and reliably.”Mikihiko Tsunematsu, Director, Telecom, Media, Entertainment, Game & Sports, Strategic Business Unit, Amazon Web Services Japan“NTT DOCOMO has led the telecommunications industry as a technology leader and has driven various innovations through its longstanding partnership with AWS. Applying AI and cloud to telecommunications unlocks new possibilities for operators to respond to customer needs more quickly and flexibly while delivering stable communication services. AWS will continue to collaborate with DOCOMO and NEC toward the evolution of telecommunications infrastructure that supports people's lives and industrial development.”(1) As of March 2, 2026, based on DOCOMO research.(2) System in which multiple AI agents, each with a specific role, automate an entire workflow toward a goal while dynamically updating their action plans according to the situation.(3) As of March 2, 2026, based on DOCOMO research.(4) Operational automation methodology for continuously aligning an environment by managing the entire state of infrastructure and application configurations (e.g., setting files and manifests) in Git and automatically detecting and synchronizing any differences.(5) Proprietary platform developed by DOCOMO that can run core network equipment from multiple vendors. 70% of DOCOMO’s commercial core network equipment operates on this platform.(6) NTT DOCOMO and NEC are Onboarding 5G SA Core Using Energy-efficient and High-performance AWS Cloud Computing Services(7) Practice of managing and provisioning infrastructure components such as servers, networks, and storage through code (e.g., YAML or JSON). This approach enables infrastructure to be automatically built, modified, and reproduced.(8) Method of automating the stages of the software release process, from building and testing to deployment, triggered by changes to the source code. It allows for the continuous integration and delivery of software.(9) Infrastructure as Code (IaC) service that allows you to define AWS resource configurations as templates in YAML or JSON format, and then automatically create, update, or delete those AWS resources based on the template.(10) Fully managed build service that compiles source code, runs tests, and produces software packages that are ready to deploy, without the need to manage servers.(11) Continuous delivery service that automates the various stages of the software release process—such as fetching source code, building, testing, approval, and deployment—by defining them as stages and automatically orchestrating their execution.(12) Family of processors designed by AWS for its cloud computing services. Graviton2 and Graviton3 are the- second and third-generation processors, respectively. For more information, see AWS’s website.(13) NTT DOCOMO and NEC Reduce Power Consumption for 5G SA Core by an Average of 72% Using AWS Graviton2, followed by a Successful Onboarding of 5G SA Core on Hybrid Cloud(14) Database system for storing and managing the change history of files and directories.(15) Fully managed agent infrastructure service that provides the execution environment, memory management, and tool integration required to build, deploy, and operate AI agents securely and at scale.(16) Standardized protocol that enables AI agents to access external tools and data sources securely and uniformly. It decouples the tool implementation from the AI interface, enhancing reusability and extensibility.ShareAbout NTT DOCOMONTT DOCOMO, Japan’s leading mobile operator with over 91 million subscribers, is one of the global leaders in 3G, 4G and 5G mobile network technologies. Under the slogan "Bridging Worlds for Wonder & Happiness," DOCOMO is actively collaborating with global partners to expand its business scope from mobile services to comprehensive solutions, aiming to deliver unsurpassed value and drive innovation in technology and communications, ultimately to support positive change and advancement in global society. https://www.docomo.ne.jp/english/About NECThe NEC Group leverages technology to create social value and promote a more sustainable world where everyone has the chance to reach their full potential. NEC Corporation was established in 1899. Today, the NEC Group’s approximately 110,000 employees utilize world-leading AI, security, and communications technologies to solve the most pressing needs of customers and society.⁠https://www.nec.com/en/About DOCOMO BUSINESSNTT Communications Corporation changed its name to NTT DOCOMO BUSINESS, Inc. on July 1, 2025. As an Industrial and Regional DX Platformer that drives digital transformation across industries and communities, we are enabling the development of a decentralized, autonomous, and collaborative society where businesses and communities can thrive sustainably. Our mission is to unlock new value and help create prosperity for all. https://www.ntt.com/en/index.html Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

KAWASAKI, Japan, Mar 2, 2026 - (JCN Newswire via SeaPRwire.com) - Fujitsu Limited today announced the launch of Uvance for Retail, a solution that integrates data onto a robust and secure cloud. The solution, which leverages Fujitsu's accumulated business knowledge and implementation capabilities, also incorporates advanced technologies such as agentic AI. By seamlessly connecting fragmented data and operations across retail sites, Fujitsu aims to enhance both on-site execution capabilities and management decision-making and support the sustainable growth and competitiveness of Japan's retail industry.Even as AI and digital technologies evolve rapidly, the Japanese retail industry faces extremely complex and structural challenges such as population decline, intensifying competition, labor shortages, and rising costs. Underlying these challenges is the overwhelming amount of data required for decision-making compared to other industries, coupled with the current situation where systems are fragmented by operation and data is scattered. Furthermore, data structures differ among manufacturers and wholesalers, leading to data silos and making cross-sectional utilization difficult. As a result, people are forced to make decisions without fully utilizing vast amounts of data, leading to increased burden. This situation undermines the agility that the retail industry has traditionally demonstrated, leading to a decline in competitiveness.For over 50 years, Fujitsu has supported the Japanese retail industry, and possesses a deep understanding of the business and related data structures developed through discussions with numerous customers and various business endeavors. Furthermore, by welcoming GK Software and BrainPad Inc. into the group, Fujitsu has strengthened its comprehensive support system, integrating industry-rooted knowledge with cutting-edge technology. By providing this accumulated retail industry knowledge and technology as Uvance for Retail, which transforms on-site execution and management decision-making as one, Fujitsu aims to enhance corporate agility and support the sustainable growth of the Japanese retail industry.Uvance for Retail comprehensively provides the capabilities necessary for retail business growth, with data and AI at its core. Fujitsu's retail-specialized consultants define management and operational challenges, leveraging their years of industry expertise to design an ideal state that includes business processes and core systems. Subsequently, offerings incorporating agentic AI are implemented by system engineers with deep retail knowledge, ensuring their effective utilization in daily operations. AI rooted in business processes enables advanced decision-making and operational autonomy. Fujitsu also provides the platform that safely connects operations, systems, and data for supporting these. Through Uvance for Retail, Fujitsu aims to innovate experiences for consumers and employees, enhance supply chains, and advance the future of retail.Uvance for Retail: Value creation and visionExhibition at RetailTech JAPAN 2026Fujitsu will exhibit at RetailTech JAPAN 2026, held at Tokyo Big Sight from March 3 to March 6, 2026. Fujitsu will focus on the value provided by Uvance for Retail through data and AI, showcasing various use cases as exhibition demos.Overview of main exhibits for Uvance for Retail1. Enhancing customer touchpoints with causal inference AIFor companies struggling to provide personalized experiences to all customers due to labor shortages, thereby missing opportunities for loyalty improvement, Fujitsu will support a deeper understanding of customers using its unique causal inference AI. Fujitsu's causal inference AI is characterized by its ability to clarify not just correlations but the "why" behind customer actions and outcomes, based on vast and complex operational and customer data. Using a proprietary algorithm, it can rapidly explore causal relationships even in data involving thousands of variables and a mix of operational, customer, and external factors. Visitors can see concrete examples of how AI reveals the causal structure behind customer behavior and needs, leading to enhanced customer service and touchpoints.2. Advanced management and operational decision-making with multi-AI agentsApparel merchandisers are required to accurately grasp the situation of each store and issue optimal instructions promptly. However, due to data fragmentation across different operations and systems, decision-making takes time, leading to missed opportunities. Fujitsu's multi-AI agent system enables multiple AI agents with different roles to collaborate, making cross-functional judgments and providing support across the entire operation. It presents the analysis results of each agent in an easy-to-understand manner and facilitates subsequent actions based on human judgment, enabling swift and effective decision-making.In the exhibition demo, Fujitsu's AI agent Watomo analyzes various data, notifies merchandisers of alarms that need attention, and performs simulations with merchandisers on how to address operational issues. Visitors can see concrete examples of how AI agents support advanced human decision-making and on-site responses.Press Conference MaterialsHeld on March 2, 2026Presentation materials and movie *Coming soonAbout FujitsuFujitsu’s purpose is to make the world more sustainable by building trust in society through innovation. As the digital transformation partner of choice for customers around the globe, our 113,000 employees work to resolve some of the greatest challenges facing humanity. Our range of services and solutions draw on five key technologies: AI, Computing, Networks, Data & Security, and Converging Technologies, which we bring together to deliver sustainability transformation. Fujitsu Limited (TSE:6702) reported consolidated revenues of 3.6 trillion yen (US$23 billion) for the fiscal year ended March 31, 2025 and remains the top digital services company in Japan by market share. Find out more: global.fujitsuPress ContactsFujitsu LimitedPublic and Investor Relations DivisionInquiries Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

RAHWAY, NJ and TOKYO, Mar 2, 2026 - (JCN Newswire via SeaPRwire.com) - Merck & Co., Inc., Rahway, NJ, USA (known as MSD outside of the United States and Canada) and Eisai (Headquarters: Tokyo, CEO: Haruo Naito) today announced the first presentation of results from the Phase 3 LITESPARK-011 trial evaluating the dual oral regimen of WELIREG® (belzutifan), Merck & Co., Inc., Rahway, NJ, USA’s first-in-class oral hypoxiainducible factor-2 alpha (HIF-2α) inhibitor, plus LENVIMA® (lenvatinib), an orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, for the treatment of patients with advanced renal cell carcinoma (RCC) whose disease progressed on or after treatment with anti-programmed death receptor-1 (PD-1)/ programmed death-ligand 1 (PD-L1) therapy. These data are being presented as a late-breaking oral abstract at the 2026 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium (abstract #LBA417) and are included in the official ASCO GU Press Program.At a pre-specified interim analysis with a median follow-up of 29.0 months (range, 19.3-49.2), WELIREG plus LENVIMA demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression-free survival (PFS), reducing the risk of disease progression or death by 30% (HR=0.70 [95% CI, 0.59-0.84]; p=0.00007) compared to cabozantinib. For WELIREG plus LENVIMA, the median PFS was 14.8 months (95% CI, 11.2-16.6) versus 10.7 months (95% CI, 9.2-11.1) for cabozantinib. A trend toward improvement in overall survival (OS), the trial’s other primary endpoint, was also observed for WELIREG plus LENVIMA (HR=0.85 [95% CI, 0.68-1.05]; p=0.06075). The median OS was 34.9 months (95% CI, 27.5-NR) for WELIREG plus LENVIMA versus 27.6 months (95% CI, 24.0- 31.4) for cabozantinib. The trial is continuing, and OS will be evaluated at a subsequent analysis per the clinical trial protocol.Based on data from the LITESPARK-011 trial, the U.S. Food and Drug Administration (FDA) has accepted two supplemental New Drug Applications (sNDA) for review seeking approval for WELIREG plus LENVIMA for the treatment of adult patients with advanced RCC with a clear cell component following a PD-1 or PD-L1 inhibitor. The FDA set a Prescription Drug User Fee Act (PDUFA), or target action date, of October 4, 2026, for both the WELIREG and LENVIMA sNDAs. Merck & Co., Inc., Rahway, NJ, USA and Eisai will also discuss these data with regulatory authorities worldwide to support potential submissions outside the United States.“Choosing the right treatment for patients with advanced renal cell carcinoma after immunotherapy has been an ongoing challenge, and treatment options in this setting had not previously been evaluated against a current standard of care tyrosine kinase inhibitor in a Phase 3 trial,” said Dr. Robert Motzer, Principal Investigator and Genitourinary Medical Oncologist, Memorial Sloan Kettering Cancer Center. “The LITESPARK-011 study demonstrated a 30% reduction in the risk of disease progression or death with belzutifan plus lenvatinib compared to cabozantinib, and 52.6% of patients experienced a response to treatment. These findings mark a critical step forward for these patients.”“The LITESPARK-011 trial highlights the potential of this first-of-its-kind combination regimen to deliver a meaningful benefit for patients with advanced renal cell carcinoma whose disease progresses after PD-1/L1 therapy,” said Dr. M. Catherine Pietanza, Vice President, Global Clinical Development, MSD Research Laboratories. “These WELIREG plus LENVIMA data demonstrate important progress for patients with advanced renal cell carcinoma and reinforce our commitment to improving the lives of patients through innovative treatment strategies.”“The LITESPARK-011 results reinforce LENVIMA's established role in renal cell carcinoma and highlight the potential of this novel combination to address an area of significant unmet need,” said Dr. Corina Dutcus, Senior Vice President, Oncology Global Clinical Development Lead at Eisai. “The acceptance of this regulatory filing is an important milestone, and we remain committed to working toward approval to bring this option to patients as soon as possible. We are grateful to the patients, their families, and the investigators, whose dedication made this research possible.”Additional findingsData for objective response rate (ORR) and duration of response (DOR), two key secondary endpoints, were also reported. At the first interim analysis with a median follow-up of 19.6 months (range, 9.9-39.8), WELIREG plus LENVIMA met ORR, demonstrating a statistically significant improvement compared to cabozantinib. A confirmed ORR of 52.6% (95% CI, 47.3-57.7) was observed for WELIREG plus LENVIMA versus 39.6% (95% CI, 34.6-44.8) for cabozantinib. At the second interim analysis with a median follow-up of 29.0 months, the median DOR was 23.0 months (95% CI, 2.0-44.3+) for WELIREG plus LENVIMA versus 12.3 months (95% CI, 1.8+-35.9+) for cabozantinib.WELIREG plus LENVIMA was administered to 370 patients and cabozantinib was administered to 371 patients. Grade ≥3 treatment-related adverse events (TRAEs) occurred in 71.6% of patients receiving WELIREG plus LENVIMA versus 65.8% of patients receiving cabozantinib. Adverse events led to treatment discontinuation in 11.1% of patients receiving WELIREG plus LENVIMA and in 11.3% of patients receiving cabozantinib, respectively. Serious adverse events were observed in 51.6% of patients receiving WELIREG plus LENVIMA versus 43.9% of patients receiving cabozantinib, and AEs led to death in 5.4% of patients (two were treatment-related: thrombotic microangiopathy [n=1] and pneumonitis [n=1]) versus 3.2% (one was treatment-related: hemoptysis [n=1]) of patients, respectively.LITESPARK-011 is part of a comprehensive late-stage clinical development program for WELIREG comprised of several Phase 2 and Phase 3 trials in pheochromocytoma and paraganglioma, von HippelLindau disease-associated neoplasms and RCC. The Phase 3 LITESPARK-012 trial is evaluating the addition of WELIREG to KEYTRUDA® (pembrolizumab), Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, plus LENVIMA in the first-line advanced RCC disease setting.WELIREG is approved in the U.S., European Union (EU), Japan and other countries for the treatment of adult patients with advanced clear cell RCC following a PD-1/PD-L1 inhibitor and 1-2 VEGFTKIs based on results from the Phase 3 LITESPARK-005 trial.KEYTRUDA plus LENVIMA is approved in the U.S., the EU, Japan and other countries for the treatment of advanced RCC. Lenvatinib is approved as KISPLYX for advanced RCC in the EU.LENVIMA in combination with everolimus is approved in the U.S., EU and other regions for the treatment of adult patients with advanced RCC following one prior anti-angiogenic therapy.Dr. Motzer has provided consulting and advisory services for Merck & Co., Inc., Rahway, NJ, USA and Eisai.About LITESPARK-011LITESPARK-011 is a randomized, open-label Phase 3 trial (ClinicalTrials.gov, NCT04586231) evaluating WELIREG in combination with LENVIMA compared to cabozantinib for the treatment of patients with advanced clear cell RCC that has progressed on or after anti-PD-1/L1 therapy. The dual primary endpoints are PFS per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) as assessed by blinded independent central review (BICR) and OS. Key secondary endpoints include ORR per RECIST v1.1 as assessed by BICR, DOR per RECIST v1.1 as assessed by BICR, and safety. The trial enrolled 747 patients who were randomized to receive WELIREG (120 mg orally once daily) plus LENVIMA (20 mg orally once daily) or cabozantinib (60 mg orally once daily).About renal cell carcinomaRenal cell carcinoma is the most common type of kidney cancer, with about nine out of 10 kidney cancer diagnoses being RCC.1 In 2022, there were about 435,000 new cases of kidney cancer and approximately 156,000 deaths from the disease worldwide.2 RCC is about twice as common in men as in women.1 Most cases of RCC are discovered incidentally during imaging tests for other abdominal diseases. Approximately 30% of patients with kidney cancer are diagnosed at an advanced stage.3About Merck & Co., Inc., Rahway, NJ, USA’s research in genitourinary cancersMerck & Co., Inc., Rahway, NJ, USA is advancing research aimed at helping transform the treatment landscape and broaden options for people with genitourinary (GU) cancers, including bladder, kidney and prostate cancers. Globally, GU cancers account for an estimated 2.6 million new cancer diagnoses each year, equaling over 1 in 8 of all cancer incidences. Through a robust clinical development program with more than 50 clinical trials evaluating more than 22,000 patients around the world, Merck & Co., Inc., Rahway, NJ, USA is investigating the potential of several portfolio medicines and pipeline assets, leveraging multiple novel combination strategies, across various stages of disease, to help address unmet needs in GU cancers.About WELIREG® (belzutifan) 40 mg tablets, for oral useWELIREG, Merck & Co., Inc., Rahway, NJ, USA’s first-in-class hypoxia-inducible factor 2 alpha (HIF-2α) inhibitor, is an orally administered small-molecule designed to reduce transcription and expression of HIF-2α target genes associated with cellular proliferation, angiogenesis and tumor growth. By inhibiting HIF-2α signaling, WELIREG aims to disrupt key pathways certain tumors may use to adapt to low-oxygen conditions, including those that help promote abnormal blood vessel formation and support tumor survival.WELIREG has demonstrated antitumor activity in certain von Hippel-Lindau (VHL) disease-associated tumors, renal cell carcinoma and in pheochromocytoma or paraganglioma. As part of a broader clinical program, Merck & Co., Inc., Rahway, NJ, USA continues to research WELIREG monotherapy and combination approaches for people with genitourinary, breast and gynecologic cancers across a range of treatment settings to further define where HIF-2α inhibition may provide clinical benefit and to better understand which patients are most likely to respond.About LENVIMA® (lenvatinib); available as 10 mg and 4 mg capsulesLENVIMA, discovered and developed by Eisai, is an orally available multiple receptor tyrosine kinase inhibitor that inhibits the kinase activities of vascular endothelial growth factor (VEGF) receptors VEGFR1 (FLT1), VEGFR2 (KDR), and VEGFR3 (FLT4). LENVIMA inhibits other kinases that have been implicated in pathogenic angiogenesis, tumor growth, and cancer progression in addition to their normal cellular functions, including fibroblast growth factor (FGF) receptors FGFR1-4, the platelet derived growth factor receptor alpha (PDGFRα), KIT, and RET. In syngeneic mouse tumor models, LENVIMA decreased tumor-associated macrophages, increased activated cytotoxic T cells, and demonstrated greater antitumor activity in combination with an anti-PD-1 monoclonal antibody compared to either treatment alone. LENVIMA has been approved for the indications below.Thyroid cancer- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable thyroid cancerThe United States: The treatment of patients with locally recurrent or metastatic, progressive, radioiodine-refractory differentiated thyroid cancer (DTC)Europe: The treatment of adult patients with progressive, locally advanced or metastatic, differentiated (papillary/follicular/Hürthle cell) thyroid carcinoma (DTC), refractory to radioactive iodine (RAI)Hepatocellular carcinoma- Indication as monotherapy(Approved mainly in Japan, the United States, Europe, China and Asia)Japan: Unresectable hepatocellular carcinomaThe United States: The first-line treatment of patients with unresectable hepatocellular carcinoma (HCC)Europe: The treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have received no prior systemic therapy- Indication in combination with KEYTRUDA (generic name: pembrolizumab) and transarterial chemoembolization(Approved in China)Thymic carcinoma- Indication as monotherapy (Approved in Japan)Japan: Unresectable thymic carcinomaRenal cell carcinoma (In Europe other than the United Kingdom, the agent was launched under the brand name Kisplyx®)- Indication in combination with everolimus(Approved mainly in the United States, Europe and Asia)The United States: The treatment of adult patients with advanced renal cell carcinoma (RCC) following one prior antiangiogenic therapyEurope: The treatment of adult patients with advanced renal cell carcinoma following one prior vascular endothelial growth factor (VEGF) targeted therapy- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Radically unresectable or metastatic renal cell carcinomaThe United States: The first-line treatment of adult patients with advanced renal cell carcinomaEurope: The first-line treatment of adult patients with advanced renal cell carcinomaEndometrial carcinoma- Indication in combination with KEYTRUDA(Approved mainly in Japan, the United States, Europe and Asia)Japan: Unresectable, advanced or recurrent endometrial carcinoma that progressed after cancer chemotherapyThe United States: The treatment of patients with advanced endometrial carcinoma that is pMMR or not microsatellite instability-high (MSI-H), as determined by an FDA-approved test, who have disease progression following prior systemic therapy in any setting and are not candidates for curative surgery or radiationEurope: The treatment of adult patients with advanced or recurrent endometrial carcinoma (EC) who have disease progression on or following prior treatment with a platinum-containing therapy in any setting and are not candidates for curative surgery.About the Eisai and Merck & Co., Inc., Rahway, NJ, USA Strategic CollaborationIn March 2018, Eisai and Merck & Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, through an affiliate, entered into a strategic collaboration for the worldwide co-development and cocommercialization of LENVIMA. Under the agreement, the companies jointly develop, manufacture and commercialize LENVIMA, both as monotherapy and in combination with Merck & Co., Inc., Rahway, NJ, USA’s anti-PD-1 therapy, KEYTRUDA, and HIF-2α inhibitor, WELIREG.Eisai’s focus on cancerEisai acknowledges “Oncology” as one of its key strategic areas, and will continue to focus on the discovery and development of anti-cancer drugs within drug discovery domains including “microenvironment”, “protein integrity and homeostasis”, and “cell lineage and cell differentiation” under the Deep Human Biology Learning (DHBL) drug discovery and development organization. Eisai aspires to discover innovative new drugs with new targets and mechanisms of action from these domains, with the aim of contributing to the cure of cancersAbout EisaiEisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept [also known as our human health care (hhc) Concept], we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, our continued commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), is demonstrated by our work on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co., Ltd.), us.eisai.com (for U.S. headquarters: Eisai Inc.) or www.eisai.eu (for Europe, Middle East, Africa, Russia, Australia, and New Zealand headquarters: Eisai Europe Ltd.), and connect with us on X (U.S. and global), LinkedIn (for U.S. and EMEA) and Facebook (global).Merck & Co., Inc., Rahway, NJ, USA’s Focus on CancerEvery day, we follow the science as we work to discover innovations that can help patients, no matter what stage of cancer they have. As a leading oncology company, we are pursuing research where scientific opportunity and medical need converge, underpinned by our diverse pipeline of more than 25 novel mechanisms. With one of the largest clinical development programs across more than 30 tumor types, we strive to advance breakthrough science that will shape the future of oncology. By addressing barriers to clinical trial participation, screening and treatment, we work with urgency to reduce disparities and help ensure patients have access to high-quality cancer care. Our unwavering commitment is what will bring us closer to our goal of bringing life to more patients with cancer. For more information, visit https://www.merck.com/research/oncology.About Merck & Co., Inc., Rahway, NJ, USAAt Merck & Co., Inc., Rahway, NJ, USA, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.merck.com and connect with us on X (formerly Twitter), Facebook, Instagram, YouTube and LinkedIn.Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USAThis news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. There can be no guarantees with respect to pipeline candidates that the candidates will receive the necessary regulatory approvals or that they will prove to be commercially successful. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2025 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).(1) American Cancer Society, “What Is Kidney Cancer” https://www.cancer.org/cancer/types/kidney-cancer/about/what-is-kidney-cancer.html(2) International Agency for Research on Cancer, World Health Organization. “Kidney fact sheet” Cancer Today, GLOBOCAN 2022. https://gco.iarc.who.int/media/globocan/factsheets/cancers/29-kidney-fact-sheet.pdf(3) E. Esterberg et al. Real-World Treatment Patterns and Clinical Outcomes Among Patients With Advanced Renal Cell Carcinoma. Clinical Genitourinary Cancer April 2024, Vol. 22, No. 2, 115–125. https://www.sciencedirect.com/science/article/pii/S1558767323002203Merck & Co., Inc., Rahway, NJ, USAMedia RelationsJulie Cunningham: +1-(617) 519-6264John Infanti: +1-(609) 500-4714Merck & Co., Inc., Rahway, NJ, USAInvestor RelationsPeter Dannenbaum: +1-(732) 594-1579Steven Graziano: +1-(732) 594-1583Eisai Co., Ltd.Public Relations:+81-(0)3-3817-5120Eisai Co., Ltd.Investor Relations:+81-(0) 3-3817-5122 Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com